SHAREABLE PDF

Can a better understanding of frailty improve the quality of life of patients with fibrotic interstitial lung diseases?

Bernard Aguilaniu

Affiliation: Medicine, University Grenoble Alpes, Grenoble, France.

Correspondence: Bernard Aguilaniu, Medicine, University Grenoble Alpes, 14 Rue Jean Bocq, Grenoble 38000, France. E-mail: b.aguilaniu@gmail.com

@ERSpublications
The fate of patients with pulmonary fibrosis is also influenced by their frailty. Hence the urgent need to evaluate these patients beyond pulmonary involvement, and to consider the decline in pulmonary function as a late warning of homeostasis erosion. http://bit.ly/2LehtmU

Cite this article as: Aguilaniu B. Can a better understanding of frailty improve the quality of life of patients with fibrotic interstitial lung diseases? *Eur Respir J* 2020; 55: 1902255 [https://doi.org/10.1183/13993003.02255-2019].

Management of progressive fibrotic interstitial lung diseases (ILDs) has long been limited to compensatory oxygen therapy and/or corticosteroids, but work in recent years has established the efficacy of new antifibrotic treatments in slowing the decline of patients with idiopathic pulmonary fibrosis [1]. However, many factors contribute to the tolerance and efficacy of new drugs in patients with ILDs.